Umeclidinium Bromide and Vilanterol Trifenatate Inhalation Powder

Cada, Dennis J.; Ingram, Kyle; Leonard, James; Baker, Danial E.

doi:10.1310/hpj4906-554

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UMEC/VI combination therapy was developed in the form of a multi-dose dry powder inhalational device. 27 Each inhalation provides a pre-set pharmacological dosage, comprising 22 mcg of vilanterol and 55 mcg of umeclidinium, to be taken once a day approximately every 24 hours. In this way, an efficient LABA-LAMA synergism of action is achieved, which provides the pharmacological basis underlying the reported improvements in respiratory function, that in turn drive the consequent clinical advantages.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

Pelaia¹,

Bannera²,

Rotundo³

et al. 2023

COPD

View full text Add to dashboard Cite

Background The pharmacological association umeclidinium/vilanterol (UMEC/VI) allows to implement a very effective dual bronchodilation in chronic obstructive pulmonary disease (COPD), thus optimizing bronchodilating therapy. Methods The main purpose of our real-world observational study was to evaluate in COPD patients the effects of UMEC/VI on lung function and respiratory symptoms. Functional and clinical parameters were assessed at baseline, and after 52 weeks of treatment with this combined double inhaled therapy. Results We enrolled 110 subjects suffering from COPD. A 12-month UMEC/VI treatment induced significant improvements in total lung capacity (TLC) (p < 0.05), and residual volume (RV) (p < 0.0001). Pulmonary deflation was paralleled by significant increases of forced expiratory volume in one second (FEV 1 ) (p < 0.0001), forced vital capacity (FVC) (p < 0.01), forced expiratory flow between 25% and 75% of FVC (FEF 25–75 ) (p < 0.0001) and diffusion capacity of the lung (DLCOcSB) (p < 0.05). In addition, in the same period, we also observed significant reductions of airway resistance including total resistance (R tot ) (p < 0.0001) and specific effective resistance (sR eff ) (p < 0.0001). Other improvements were detected with regard to modified British Medical Research Council (mMRC) questionnaire score (p < 0.0001), COPD Assessment Test (CAT) score (p < 0.0001), and COPD exacerbation rate (p < 0.0001). In particular, the reported changes of mMRC/CAT scores and COPD exacerbation numbers were significantly correlated with UMEC/VI–induced modifications of TLC, RV, FVC and FEV 1 . Conclusion In conclusion, our study corroborates in a real-life context the effectiveness of UMEC/VI in COPD treatment. Indeed, our broad investigational strategy has allowed to better characterize the functional mechanisms underpinning the therapeutic properties of UMEC/VI association.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

Pelaia¹,

Bannera²,

Rotundo³

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

“…Another highly important trait differentiation of dry powder inhalers is the inhaler's own resistance to the flowing air. Thus, DPIs differ in the values of aspiration flow interval values necessary to activate the drug dose (54,55). In these terms, two types of dry powder inhalers can be distinguished: high resistance (optimum aspiration flow > 60 L/min, i.a.…”

Section: Currently Used Inhaler Typesmentioning

confidence: 99%

The history, current state and perspectives of aerosol therapy

et al. 2021

View full text Add to dashboard Cite

Nebulization is a very effective method of drug administration. This technique has been popular since ancient times when inhalation of plants rich in tropane alkaloids with spasmolytic and analgesic effects was widely used. Undoubtedly, the invention of anasthesia in the 19th century had an influence on the development of this technique. It resulted in the search for devices that facilitated anasthesia such as pulveriser or hydronium. From the second half of the 21st century, when the first DPI and MDI inhalers were launched, the constant development of aerosol therapy has been noticed. This is due to the fact that nebulization, compared with other means of medicinal substance application (such as oral and intravenous routes of administration), is safer and it exhibits a positive dose/efficacy ratio connected to the reduction of the dose. It enables drugs administration through the lung and possesses very fast onset action. Therefore, various drugs prescribed in respiratory diseases (such as corticosteroids, β-agonists, anticholinergics) are present on the market in a form of an aerosol.

show abstract